TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03857893

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dynamic Quadripolar Radio-Frequency treatment
Description: Novel low-energy Dynamic Quadripolar Radio-frequency thermal treatment through Eva™ Device. Eva™ Device combines both advanced VDR™ technology (Vaginal Dynamic Radiofrequency) and RSS™ (Radiofrequency Safely System) technology.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: pH-Cream
Description: 1g of Cetomacrogol cream (pH-cream) to self-administered with a vaginal applicator for 12 weeks (one dose every three days)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pH-Cream
Description: 1g of Cetomacrogol cream (pH-cream) to self-administered with a vaginal applicator for 12 weeks (one dose every three days)
Study: NCT04158297

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ESWL vs SOPIL
Description: To compare the efficacy of single operator pancreatoscopy (SOP) with intracorporeal lithotripsy (SOPIL) to extracorporeal shock wave lithotripsy (ESWL) for the treatment of main pancreatic duct stones (MPDS) in patients with chronic pancreatitis.
Study: NCT04944329

Intervention type: PROCEDURE
Intervention: Hip fracture surgery
Description: Hip fracture surgery
Study: NCT01031485

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Milk peptides and plant sterols

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT02090985

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Lipomodelling of symptomatic peri-stomal skin contour abnormalities
Study: NCT00873275

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Performed on blood collected at Day -6, Day 0 and Day 7 (1 week after the first cycle of chemotherapy) from treatment and at the end of treatment

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Day 0, day 7 before treatment, 1/2 hour after the start of treatment, 1, 2, 3, 4, and 8 hours after the start of treatment.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: positron emission tomography (PET)
Description: Patients will undergo PET scan imaging as part of their original staging or at baseline. If the PET scan was more than 2 weeks prior to Day 0 from study treatment, there will be a PET scan at Day 0. In any case there will be a PET scan when the patient completes treatment.
Study: NCT04312204

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sintilimab combined with Gemcitabine and Carboplatin
Description: The patients will received Gemcitabine1000mg/m2(d1,d8)(iv)+carboplatin AUC 5 (d1)(iv),4 cycles, Sintilimab 200 mg (3mg/kg when the weight \<40kg ) (d1) (iv) in one cycle every 3 weeks, until PD or death.~Radiological examinations (according to the RECIST 1.1 criteria) at baseline will be repeated for tumor response evaluation following every two cycles of chemotherapy. Patients will be followed up to 30 days after the last dose of study chemotherapy, and then every 3 months.
Study: NCT02966262

Intervention type: DEVICE
Intervention: Optical coherence tomography
Description: Intracoronary imaging device which can precisely observe intracoronary structures
Study: NCT05199181

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Full pulpotomy
Description: After applying the rubber dam. Caries, and weak tissues were removed, and the endodontic access was prepared with a carbide bur. Most of the pulp was removed with a sterile high-speed diamond bur under sterile saline solution irrigation and amputated to the canal orifices level. Hemostasis was achieved by irrigation of the cavity with the same solution and an application of small cotton pellets for max.10 min. White Mineral Trioxide Aggregate was mixed according to the manufacturer´s instructions and was placed against the wound after successful hemostasis using an amalgam carrier and packed using an amalgam standard condenser. The material was adapted and a moistened cotton pellet was placed directly over the Mineral Trioxide Aggregate. After 15 minutes, the cotton was removed and the tooth was restored with amalgam. A postoperative radiograph was taken after restoration, general care instructions were given to the patients, and the recommendation of three analgesic intakes.
Study: NCT04044378

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Famitinib
Description: famitinib with RP2D orally daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Famitinib
Description: famitinib with RP2D orally daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Famitinib
Description: famitinib with RP2D orally daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ifosfamide
Description: ifosfamide 1.8g/m2/d d1-3, 15-17 Q4W infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Camrelizumab
Description: camrelizumab 200mg infusion once Q2W
Study: NCT02252913

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Volitinib
Description: oral administration
Study: NCT02287129

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Biopsy
Description: translational analysis
Study: NCT03443193

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise training
Description: Patients will undergo three weekly exercise training sessions with periodized high-intensity interval training and resistance training for a period of 12 weeks.
Study: NCT03945032

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: TICOP
Description: Parent moves the cursor by analogy on their mobile phone (as a visual anagogic scale) four times per year (baseline; month 4; month 8 and month 12).
Study: NCT02494778

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pridopidine
Description: 45 mg BID
Study: NCT00825019

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: amibegron (SR58611A)
Description: oral administration of 2x 700 mg/day in 12h intervals

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: oral administration in 12h intervals
Study: NCT02252913

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: intravenous injection
Study: NCT02926781

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Dask Advanced Sinus kit
Description: a kit of specially designed drills for closed sinus lift
Study: NCT00825019

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: paroxetine
Description: oral administration of 20 mg/day
Study: NCT01539278

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Adenotonsillectomy
Description: Tonsils and adenoids are surgically removed
Study: NCT02926781

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dask Advanced Sinus kit
Description: a kit of specially designed drills for closed sinus lift
Study: NCT02816502

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Stress Management Skill Building Program A
Description: Subject will meet with the instructor and other students in the group once a week and complete homework and track amount of practice during the week.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Stress Management Skill Building Program B
Description: Subject will meet with the instructor and other students in the group once a week and complete homework and track amount of practice during the week.
Study: NCT02342249

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: VX-787 300 mg
Description: A oral dose of 300 mg VX-787 tablet will be administered over 5-6 days.
Study: NCT01539278

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Observation alone / no intervention
Description: Patients are observed over time, no surgery is done, subjects complete QOL questionnaires at set intervals
Study: NCT03909932

Intervention type: OTHER
Intervention: Observational study : no intervention
Description: Observational study : only exporting data
Study: NCT03335956

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CORT125281, 40mg, fasted
Description: CORT125281 is supplied as capsules for oral dosing

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone 25mg, fasted
Description: Challenge Agent, Dose and Route of Administration:~Standard release 25 mg tablets, orally administered

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone 25mg, fasted
Description: Challenge Agent, Dose and Route of Administration:~Standard release 25 mg tablets, orally administered

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone 25mg, fasted
Description: Challenge Agent, Dose and Route of Administration:~Standard release 25 mg tablets, orally administered
Study: NCT03045185

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: RET using Ciprofloxacin 100mg, and Metronidazole 100mg.
Description: First Treatment Visit: Tooth isolation, access, pulp extirpation and root canal irrigation with 0.5% sodium hypochlorite. Canal negotiation, canal drying using paper points. Delivery of the Bi antibiotic paste (mixture of Bi antibiotic paste (Ciprofloxacin 100mg and Metronidazole 100mg with sterile water). Sealing tooth access with glass ionomer cement.~Second Treatment Visit: Tooth analgesia using plain local analgesics, isolatation and re-access as described above. Irrigation of root canal system using normal saline followed by paper point dying. Initiation of bleeding through insertion of a sterile 23-gauge needle with a length of 2 mm beyond the working length into the periapical tissues. Access sealed using Portland cement, followed by glass ionomer and then composite resin.
Study: NCT01844492

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: The PARTNER Intervention
Description: The PARTNER intervention (PAiring Re-engineered ICU Teams with Nurse-driven Emotional Support and Relationship-building) consists of: 1) institution of a clinical pathway for family support overseen by ICU staff nurses; 2) advanced communication skills training for ICU staff nurses; 3) a multifaceted strategy to support implementation of the clinical pathway for family support.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: ICU Usual Care Control
Description: The control group will receive usual care, in which the frequency and content of clinician-family communication is determined by the clinical team according to their usual practice. No study ICU has a protocolized approach to family communication and instead clinicians determine the timing and frequency of communication with families. All sites have palliative care services.
Study: NCT03747588

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Minimally-invasive pancreaticoduodenectomy
Description: Minimally-invasive pancreaticoduodenectomy for resection of pancreatic tumor

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Open pancreaticoduodenectomy
Description: Open pancreaticoduodenectomy for resection of pancreatic tumor
Study: NCT02654834

Intervention type: OTHER
Intervention: Exposure to nitrous oxide or other volatile anesthetics
Description: No intervention, but routine work-place exposure to volatile anesthetics
Study: NCT02023281

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: The experimental group will engage in mild-moderate level of exercise. This program will be structured and clinically supervised. Exercise will take place 2-3 days per week for a duration of 30-45 mins. for 12 weeks.
Study: NCT03974425

Intervention type: DRUG
Group type: OTHER
Intervention: Aflibercept Injection [Eylea]
Description: intravitreal injection of Aflibercept in resistant DME.
Study: NCT02050516

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: micro-well group culture dish
Description: an embryo culture dish containing nine micro-wells in the middle.
Study: NCT04553523

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hydrus Microstent
Description: Crescent-shaped nitinol device intended as a permanent implant to provide an outflow pathway for aqueous humor. The device is placed through the trabecular meshwork into Schlemm's canal immediately following placement of a monofocal IOL.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cataract surgery
Description: Cataract surgery performed using standard anesthesia and phacoemulsification techniques

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Monofocal IOL
Description: Commercially available monofocal intraocular lens as determined by the investigator
Study: NCT00581035

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Prevenar and Meningitec
Description: 1 dose of Prevenar at 2,3.5,6 and 12 months and 1 dose of Meningitec at 2,6 and 12 months

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Prevenar
Description: 1 dose at 2,3.5,6 and 12 months

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Meningitec
Description: 1 dose at 2,6 and 12 months
Study: NCT01942018

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: POEM
Description: Patients will receive Per oral endoscopic myotomy (POEM) for symptomatic gastroesophageal junction outflow obstruction (EGOO)
Study: NCT02035670

Intervention type: OTHER
Intervention: Two-step diagnostic strategy
Description: The first step is to differentiate FUO according to the onset of disease and invasive pathogens. Apart from collecting detailed present medical history and careful physical examination, it focuses on seeking the clues of bacterial invasion two weeks before the fever onset from five aspects.To finish this part, the doctor needs to ask for informations following a list we already made, which covers more than forty definite items. If some of these items were proved existed, result of first step would be positive.~The second step is calculating the integral score of inflammatory biomarkers and vital diagnostic clues, WBC\& N, ESR, CRP, LDH, SF, ANCA, ANA, RF, PCT and T-Spot, as well as the clinical findings were included in this integrating system.The results of these items will be recorded and calculated with certain interval of time. If the score were more than nine, this part would be considered. positive.
Study: NCT03373708

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epirubicin
Description: 100mg/m2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 600mg/m2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 600mg/m2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: 75mg/m2(TC), 100mg/m2(EC-T)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: 75mg/m2(TC), 100mg/m2(EC-T)
Study: NCT02050516

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: micro-well group culture dish
Description: an embryo culture dish containing nine micro-wells in the middle.
Study: NCT01669226

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PEip (weekly) and TCiv
Description: IP: cisplatin 50mg/m2 and etoposide 100mg/m2, weekly, 4 times; 14 days later IV: paclitaxel 175mg/m2 plus carboplatin AUC 5 or docetaxel 60-75mg/m2 plus carboplatin AUC 5
Study: NCT03373708

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Goserelin acetate
Description: 3.6mg every month

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tamoxifen
Description: 10mg twice daily oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letrozole
Description: 2.5mg every daily oral
Study: NCT01669226

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TCiv
Description: IV: paclitaxel 175mg/m2 plus carboplatin AUC 5 or docetaxel 60-75mg/m2 plus carboplatin AUC 5
Study: NCT03335956

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Prednisone 25mg, fasted
Description: Challenge Agent, Dose and Route of Administration:~Standard release 25 mg tablets, orally administered

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Prednisone 25mg, fasted
Description: Challenge Agent, Dose and Route of Administration:~Standard release 25 mg tablets, orally administered

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Prednisone 25mg, fasted
Description: Challenge Agent, Dose and Route of Administration:~Standard release 25 mg tablets, orally administered

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone 25mg, fasted
Description: Challenge Agent, Dose and Route of Administration:~Standard release 25 mg tablets, orally administered

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone 25mg, fasted
Description: Challenge Agent, Dose and Route of Administration:~Standard release 25 mg tablets, orally administered

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Prednisone 25mg, fasted
Description: Challenge Agent, Dose and Route of Administration:~Standard release 25 mg tablets, orally administered

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Prednisone 25mg, fasted
Description: Challenge Agent, Dose and Route of Administration:~Standard release 25 mg tablets, orally administered

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral capsule, fasted
Description: Reference Therapy, Dose and Route of Administration:~Placebo capsule, orally administered

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral capsule, fasted
Description: Reference Therapy, Dose and Route of Administration:~Placebo capsule, orally administered

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral capsule, fasted
Description: Reference Therapy, Dose and Route of Administration:~Placebo capsule, orally administered

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral capsule, fasted
Description: Reference Therapy, Dose and Route of Administration:~Placebo capsule, orally administered

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pioglitazone 15mg Tablet
Description: Probe Substrate, Dose and Route of Administration:~15 Mg tablet, orally administered

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pioglitazone 15mg Tablet
Description: Probe Substrate, Dose and Route of Administration:~15 Mg tablet, orally administered

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pioglitazone 15mg Tablet
Description: Probe Substrate, Dose and Route of Administration:~15 Mg tablet, orally administered

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pioglitazone 15mg Tablet
Description: Probe Substrate, Dose and Route of Administration:~15 Mg tablet, orally administered
Study: NCT03217656

Intervention type: OTHER
Intervention: No intervention
Study: NCT00724932

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rocuronium
Description: Participants will receive an intravenous (i.v.) single bolus dose of 0.6 mg.kg-1 rocuronium. After this dose, maintenance doses of 0.1-0.2 mg.kg-1 rocuronium may be given.
Study: NCT03335956

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Pioglitazone 15mg Tablet
Description: Probe Substrate, Dose and Route of Administration:~15 Mg tablet, orally administered

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Pioglitazone 15mg Tablet
Description: Probe Substrate, Dose and Route of Administration:~15 Mg tablet, orally administered

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Pioglitazone 15mg Tablet
Description: Probe Substrate, Dose and Route of Administration:~15 Mg tablet, orally administered

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Pioglitazone 15mg Tablet
Description: Probe Substrate, Dose and Route of Administration:~15 Mg tablet, orally administered

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral capsule, fed
Description: Reference Therapy, Dose and Route of Administration:~Placebo capsule, orally administered

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone 25mg, fed
Description: Challenge Agent, Dose and Route of Administration:~Standard release 25 mg tablets, orally administered

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Prednisone 25mg, fed
Description: Challenge Agent, Dose and Route of Administration:~Standard release 25 mg tablets, orally administered

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CORT125281, 120mg, fasted
Description: CORT125281 is supplied as capsules for oral dosing

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CORT125281, 360mg, fasted
Description: CORT125281 is supplied as capsules for oral dosing
Study: NCT00226018

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Hand Adapter (Organon, Oss, the Netherlands)
Description: Randomization of acceleromyography with or without Hand Adapter to dominant or non-dominant arm. Contralateral neuromuscular transmission is measured with mechanomyography (The gold standard of neuromuscular monitoring)
Study: NCT03335956

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CORT125281, 720mg, fasted
Description: CORT125281 is supplied as capsules for oral dosing

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CORT125281, 360mg, fed
Description: CORT125281 is supplied as capsules for oral dosing

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CORT125281, 360mg
Description: CORT125281 is supplied as capsules for oral dosing twice, 12 hours apart, fasted (morning) and after evening meal
Study: NCT02342249

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: VX-787 600 mg
Description: A oral dose of VX-787 600 mg (formulated as 2\*300 mg tablets) will be administered over 5-6 days.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: VX-787 600 mg
Description: A oral dose of VX-787 600 mg (formulated as 2\*300 mg tablets) will be administered over 5-6 days.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oseltamivir 75 mg
Description: A oral dose of 75 mg Oseltamivir capsule will be administered over 5-6 days.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Subjects will receive matching placebo of Oseltamivir

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Subjects will receive matching placebo of Oseltamivir

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects will receive matching placebo of Oseltamivir